Noom Med Review: Three Price Ladders, and a Month That Is Four Weeks Long

It depends which of three ladders you land on, and none of them is the number in the advert. The Microdose GLP-1Rx programme is $49 for a three-week starter and $179 a month after that, medication included. The GLP-1Rx Plus Microdose programme is $79 then $199. A third homepage footnote quotes $149 then $349 without naming the programme. On the brand-name track the care fee is $39 to start and $99 a month ongoing, and the medication is separate — Zepbound vials at $299 a month through LillyDirect, or $1,000 to $1,100 for pens without insurance, on Noom's own figures.

Because that is how Noom's own footnote counts. It reads "$179 per month plus tax for 12 week subscription thereafter" — three months to twelve weeks makes each month four weeks, not a calendar month. The starter period is described the same way: "Initial 3 week subscription and 4 weeks of medication." A four-week cycle repeats thirteen times in a year rather than twelve. On the Microdose plan that is $2,327 a year at thirteen cycles, against $2,148 if Noom instead bills three calendar months to a twelve-week term — a $179 difference, which is exactly one extra charge. Both figures are here because Noom's wording supports the four-week reading and its checkout is the only place to confirm it.

On the Microdose plan, $49 for the starter plus twelve further four-week cycles at $179 is $2,197 in the first year, settling at $2,327 a year after that. On GLP-1Rx Plus Microdose it is $2,467 in year one and $2,587 after. On the brand-name Zepbound route it is $338 for the first month plus eleven at $398, or $4,716 — cheaper than Ro's $6,916 for the same drug, because Noom is charging a care fee and letting LillyDirect sell you the medication at $299.

There is no way to tell from the website, and that is the finding. Four numbers were live on August 7, 2026: a "$49 Limited-Time Offer" banner across the homepage, a "starting at $79" answer in the FAQ on noom.com/med/ for what appears to be the same microdose programme, and homepage footnotes quoting $79/$199 and $149/$349. Noom's own buyflow code carries plan tiers named for experiments — including variants labelled telex294a and telex294b and one called "price-update" — which is what simultaneous price testing looks like from the outside. Read the figure on your own checkout screen, not the one on the page that sent you there.

On the microdose plans, yes. The footnote on noom.com/med/glp1-microdose/ says the price "Includes medication (if prescribed) and full program access." That makes $179 genuinely all-in and one of the cheaper ongoing compounded GLP-1 prices anywhere. On the brand-name track, no: the $39-then-$99 is a care fee, and Wegovy, Ozempic, Mounjaro or Zepbound is billed on top by the pharmacy or your insurer. Noom prices Zepbound vials at $299/mo through LillyDirect and says pens run $1,000 to $1,100 a month without insurance.

Noom will not say. Its homepage footnote states that the microdose programme is "not available in all 50 US states" and lists none of them, and no coverage list appears on noom.com/med/, on the transparency page, or in the terms. The only way to find out is to start the eligibility survey and reach the state question. That is the same gap Hers leaves, and it is worth checking before you give a card to anyone.

You can cancel before the end of the current billing period and it takes effect at the end of that period — so you keep access to what you have paid for and are not billed again. Money already paid mostly stays paid: Noom's terms say "all fees and charges assessed by us are non-refundable except as expressly promoted by Noom." The exception is statutory, not commercial — California residents may cancel before midnight of the third business day after purchase and get a refund, by post, to Noom's legal department in Princeton. Note also that renewals happen "at the price in effect at the time of the renewal," so a promotional rate is not a locked rate.